Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages

Key Points

• Analysts give Candel Therapeutics a consensus "Hold" rating from eight analysts (2 sell, 1 hold, 5 buy) with an average 1‑year target of $18, versus the recent price around $4.83.
• Director Paul B. Manning bought 550,458 shares at $5.45 on Feb. 23, raising his holding to 2,763,527 shares and bringing insider ownership to 16.6%.
• The company reported quarterly EPS of -$0.54 versus a consensus of -$0.24 (missing by $0.30), with analysts forecasting -$1.47 for the year; market cap is about $353.8M and the 52‑week range is $4.34–$7.25.

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have earned a consensus recommendation of "Hold" from the eight analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $18.00.

A number of research analysts recently issued reports on the company. Zacks Research downgraded Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, April 7th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Candel Therapeutics in a research note on Wednesday, January 21st. Citigroup cut their price objective on Candel Therapeutics from $24.00 to $22.00 and set a "buy" rating for the company in a research note on Friday, March 13th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $25.00 price objective on shares of Candel Therapeutics in a research note on Friday, March 13th.

Insider Activity

In related news, Director Paul B. Manning acquired 550,458 shares of the business's stock in a transaction that occurred on Monday, February 23rd. The stock was bought at an average cost of $5.45 per share, for a total transaction of $2,999,996.10. Following the purchase, the director owned 2,763,527 shares in the company, valued at $15,061,222.15. The trade was a 24.87% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 16.60% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Acorn Capital Advisors LLC boosted its stake in Candel Therapeutics by 19.9% in the 2nd quarter. Acorn Capital Advisors LLC now owns 2,580,517 shares of the company's stock worth $13,057,000 after purchasing an additional 428,265 shares during the period. Vanguard Group Inc. boosted its stake in Candel Therapeutics by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company's stock worth $10,236,000 after purchasing an additional 219,563 shares during the period. Geode Capital Management LLC boosted its stake in Candel Therapeutics by 5.3% in the 4th quarter. Geode Capital Management LLC now owns 977,512 shares of the company's stock worth $5,524,000 after purchasing an additional 49,315 shares during the period. State Street Corp boosted its stake in Candel Therapeutics by 15.0% in the 4th quarter. State Street Corp now owns 792,218 shares of the company's stock worth $4,476,000 after purchasing an additional 103,452 shares during the period. Finally, Halter Ferguson Financial Inc. boosted its stake in Candel Therapeutics by 7.2% in the 4th quarter. Halter Ferguson Financial Inc. now owns 748,055 shares of the company's stock worth $4,227,000 after purchasing an additional 50,051 shares during the period. 13.93% of the stock is currently owned by institutional investors.

Candel Therapeutics Price Performance

NASDAQ CADL opened at $4.83 on Friday. Candel Therapeutics has a 52 week low of $4.34 and a 52 week high of $7.25. The firm has a market capitalization of $353.80 million, a P/E ratio of -6.80 and a beta of -0.81. The company has a quick ratio of 13.49, a current ratio of 13.49 and a debt-to-equity ratio of 0.91. The company has a 50-day moving average price of $5.18 and a 200-day moving average price of $5.39.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.30). Equities research analysts anticipate that Candel Therapeutics will post -1.47 earnings per share for the current year.

About Candel Therapeutics

Candel Therapeutics NASDAQ: CADL is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company's lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel's pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.